Evenity, customized for patients with high risk of fracture

Targeting patients at super risk of fracture, applied from this month

Amgen presents a long-term treatment strategy with Evenity→Prolia

As Amgen's new osteoporosis treatment, Evenity (Romosozumab) was applied from this month, it could be used more by patients.

 

In particular, Evenity, which has proven its strong efficacy in patients with high risk of fracture, may be useful.

 

On the 10th, Amgen held an online meeting to commemorate the launch of Evenity insurance benefits, and announced Evenity's treatment strategy in the ultra-high risk group for osteoporosis fractures.

 

Amgen's new osteoporosis treatment, Evenity (Romosozumab) was approved in May of last year as a treatment for postmenopausal women with osteoporosis at high fracture risk and for increasing bone density in men with osteoporosis at high risk of fracture.

 

Benefits for Evenity have been applied since the 1st.

 

This is when all are satisfied among patients who do not have an effect on or cannot use existing bisphosphonates ▲postmenopausal women over 65 years old ▲Bone density test result measured by dual energy radiation absorption measurement at the central bone T-score -2.5 SD or less ▲Among conditions with two or more osteoporotic fractures.

 

Patients who satisfy this condition can receive benefits once a month, up to one year.

 

Professor Kim Deok-yoon of the Department of Endocrinology at Kyunghee University Hospital announced on this day 'the latest knowledge of osteoporotic fracture treatment and customized treatment strategies for ultra-high-risk patients'.

 

He said, "One in three hip fracture patients cannot walk without help for two years, and one in four dies within 12 months."

Kim Deok-yoon, Professor of Endocrinology and Internal Medicine, Kyung Hee University Hospital

For this reason, the latest guidelines recommend that patients in these ultra-high risk groups reduce the risk of fracture through strong drug treatment.

 

Evenity can play a useful role as it has the effect of inhibiting bone resorption in addition to existing bone formation promoting agents.

 

If the bone density is the same or improved after 1 year of treatment with Evenity, treatment can be continued with another bone resorption inhibitor.

 

He said, "It is important to lower the risk of fracture with strong drugs such as Evenity from the beginning of treatment for the ultra-high-risk group of osteoporosis fracture.

 

From this month, it is expected that customized treatment for the ultra-high-risk group will be possible with the application of Evenity." He added, "It is the norm to use bone formation promoting agents first in the treatment of patients in ultra-high-risk patients, and then follow-up treatment with bone resorption inhibitors." Amgen believes that Denosumab could serve as a follow-up treatment after Evenity.

 

He agreed that "Romosozumab-Denosumab treatment will be the best combination.

 

In fact, this combination should be used to quickly get out of the risk of fracture." However, he was disappointed by the limited benefit standards.

 

He said that Evenity was considered a very useful drug for patients with super-risk patients, and since last May, he thought that even a non-reimbursed drug should be used and it would be very welcome that Evenity became a reimbursed drug this time.

 

Sang-yoon Kim, managing director of marketing at Amgen Korea's General Medison Division, said, "We will try to establish Evenity as a standard treatment for people at high risk of fractures.

 

And, we will work on long-term osteoporosis treatment strategies ranging from Evenity, which is effective for strong initial treatment to Prolia, suitable for continuous treatment in Korea.

 

I will actively seek out with the medical staff.”